Observational studyKidney & blood pressure research2026
Inflammatory Biomarkers in the Assessment of Kidney Function Decline in Long COVID Syndrome.
Observational study in Kidney & blood pressure research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionLong COVID (LC) is an inflammatory condition, affecting multiple organs, including kidneys. This study aims to identify a signature of inflammatory biomarkers that can predict, describe, and monitor kidney function decline in LC patients.
methodsA single-center observational study was carried out at the COVID Center of University of Campania "L. Vanvitelli." Patients who survived the acute phase were invited for a follow-up visit at least 12 months after discharge. Based on the estimated glomerular filtration rate (eGFR), patients were categorized in three groups: group 1: eGFR >90 mL/min × 1.73 m2, group 2: eGFR 30-89 mL/min × 1.73 m2, and group 3: eGFR <30 mL/min × 1.73 m2. The multiplex ELLA platform was employed to quantify serum levels of inflammatory biomarkers including IL-6, IL-17, IL-10, IL-1β, PTX3, TNF-α, VCAM-1, ICAM-1, and E-selectin. Associations between each biomarker level and eGFR were analyzed.
resultsA decline in the eGFR at follow-up compared to that at admission was observed. IL-6 levels increased significantly as the eGFR decreased across the groups. IL-17, IL-10, and VCAM1 levels were markedly elevated in group 3.
conclusionsAccording to our results, IL-6, IL-17, IL-10, and VCAM1 constitute a biomarker signature associated with poorer renal prognosis in LC patients. The rise in IL-6 could drive an increase in IL-17, IL-10, and VCAM1, contributing to kidney function decline. These findings may help establish a clinical and laboratory framework to predict chronic kidney disease risk in LC. Furthermore, ELLA platform appears as a useful tool for inflammatory biomarker quantification in the clinical setting.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.